BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
BridgeBio Pharma, Inc news
05.05.2022
BridgeBio Pharma's GAAP loss for 3 months of 2022 was $201.33 million, up 17.7% from $171.082 million in the previous year. Revenue increased 3.7 times to $1.694 billion from $0.462 billion a year earlier.
Source: 
investor.bridgebio.com
investor.bridgebio.com
General information
| Company name | BridgeBio Pharma, Inc |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 421 Kipling Street Palo Alto, CA 94301 United States |
| Mailing address | 421 Kipling Street Palo Alto, CA 94301 United States |
| Website | investor.bridgebio.com |
English (US) 